The global parkinson’s disease market is expected to grow at a CAGR of around 11.3% from 2020 to 2027 and expected to reach the market value of around US$ 4,764.3 Mn by 2027.
Parkinson's is a type of movement disorder that affects the ability to perform common daily activities. It is a chronic and progressive disease. It is characterized by its most common motor related symptoms like tremors (a form of rhythmic shaking), stiffness or rigidity of muscles, and slowness of movement (called bradykinesia). Also, non-motor symptoms including sleep problems, constipation, anxiety, depression, fatigue, and others. According to the American Parkinson Disease Association, there are 1 million people in the US living with Parkinson’s disease and more than 10 million people globally. Approximately 10% of Parkinson’s diagnoses occur before the age of 50 years. These diagnoses are called early onset (or young onset) Parkinson’s disease. Furthermore, strong market players present globally have a robust drug pipeline for the treatment of Parkinson's disease. Major product launches in the coming years will boost the market growth of Parkinson's disease market.
According to Clinicaltrials.gov to treat Parkinson's disease NLY01 is in Phase 2 clinical trials. The Phase 2 study is designed to access the safety, tolerability, and efficacy of NLY01 for early untreated Parkinson's disease (PD). Evidence suggests that NLY01, a pegylated form of exenatide can prove beneficial in Parkinson's disease and is being developed as a potential treatment for neurodegenerative disorders. Actual start date of the study was February 2020 and estimated completion date is August 2022.
Government involvement by providing funding for research activities
Parkinson's UK is the largest member led charitable funder of Parkinson's Europe. Till date it has invested more than US$ 121,65 Mn for the research program. Parkinson's Virtual Biotech is involved in drug discovery and development arm of Parkinson's UK that is one of the prominent organizations and a pioneer in charitable funding of Parkinson's research in Europe. The Virtual Biotech launched in March 2017 and by the end of 2019 committed over US$ 9 Mn for creating an exciting and diverse pipeline of projects at the drug discovery, preclinical, and early clinical development stages. Further, the company aims to invest at least a further US$ 24 Mn and deliver a life-changing new treatment to people with Parkinson's by the end of 2024.
High prevalence of Parkinson's disease in aging population drives the market growth
According to the estimates released by the National Institute of Environmental Health Sciences (NIEHS), nearly 1 million people in the US are living with the Parkinson’s disease. The average age of onset is about 60 years. The population prevalence increases from about 1% at age 60 to 4% by the age of 80. One clear risk factor for Parkinson disease is age. Although most people with Parkinson's first develop the disease at the age of 60, however about 5-10% of people with Parkinson have early onset disease that begins before the age of 50 as per the National Institute of Aging (NIA).
Parkinson’s disease market is segmented based on drug class and distribution channel, and patient care settings. By drug class, the market is segmented based on carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics, and other drugs. Based on distribution channel, market is segmented as hospital pharmacies, retailer pharmacies, and online pharmacies. By patient care settings the market is bifurcated into hospitals and clinics.
Based on drug class, carbidopa/levodopa is expected to account largest market share of the Parkinson’s disease market. Carbidopa/levodopa is the most effective medication for accelerating the motor symptoms of Parkinson's disease. But it is essential that co-therapeutics agents such as COMT (catechol-o-methyltransferase) inhibitors are used in combination with carbidopa/levodopa therapy. The two most common used COMT inhibitors in the treatment of Parkinson’s disease are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of solid dosage forms such as tablets and routinely prescribe in conjunction with carbidopa/levodopa. Furthermore, due to high prevalence of aging population of Parkinson’s disease demand for these drugs will grow to its fullest. Based on distribution channel, hospital pharmacies segment will continue dominating the market of Parkinson’s disease. Rising number of patient pool with frequent visits to doctors or physicians, wide availability of diagnostic laboratories and presence of skilled neurologist drive the growth of this segment. On basis of patient care settings, hospitals segment dominated the overall market by recording the largest share of the market and will continue the same trend in the forecast period. Rigorous healthcare infrastructure ad presence of skilled physicians drives the hospital segment market for Parkinson’s disease market. Clinics segment also known as outpatient clinics or ambulatory care clinics are healthcare facilities where outpatients are treated. In comparison, with hospitals, clinics hold second largest market share of the overall Parkinson's disease market. Shortage of neurologists in hospitals will ultimately result in driving the clinics segment in the forthcoming years.
North America dominates the Parkinson’s disease Market
Based on regions, North America dominates the Parkinson's disease market. According to the National Institute of Health (NIH), approx. 1.2 million people in the US are predicted to suffer from Parkinson's disease by 2030. It is the second most common neurodegenerative disorder in the US. Additionally, there are thousands of patients unaware about suffering from Parkinson's disease and continues to go undetected. As the aging population continues to grow the number of people suffering from Parkinson's disease (PD) may also continue to grow. Rising prevalence of patient pool suffering from PD, availability of reimbursement policies for treatment, bolster the regional growth of Parkinson’s disease market regionally. However, Asia Pacific regional market is expected to be the fastest growing region for Parkinson's disease. It is projected that Asia Pacific market will record a significant CAGR in the forthcoming years with the growth in this market is centered at China, Japan, and India. Rising number of generic drugs manufacturers and ageing population in this region are the factors that fuel the growth of Asia Pacific regional market.
Key companies profiled in this report involve Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories, Lundbeck, UCB, Valeant Pharmaceuticals, Acadia, and among others.
Market By Drug Class
Dopamine receptor agonists
Market By Distribution Channel
Market By Patient Care Setting
Market By Geography
Middle East & Africa
Portable medical device is expected to reach a market value of around US$ 4,764.3 Mn by 2027.
The Parkinson’s disease market is expected to grow at a CAGR of around 11.3% from 2020 to 2027.
Based on drug class, carbidopa/levodopa is the leading segment in the overall market.
High government involvement and rising ageing population are the prominent factors that drive the demand for Parkinson’s disease market.
Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories, Lundbeck, UCB, Valeant Pharmaceuticals, Acadia, and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years